COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0
作者：
Petropoulos, A. [1 ]
Cooney, P. [2 ]
Patidar, M. [3 ]
Gudala, K. [3 ]
Tiwari, S. [4 ]
Brennan, R. [2 ]
Kapsogeorgiou, K. [1 ]
Cheilas, G. [1 ]
Banhazi, J. [5 ]
机构：
[1] Novartis Hellas SACI, Athens A1, Greece
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Healthcare Private Ltd, Hyderabad, India
[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
[41]   The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment [J].
Ceri J. Phillips .
CNS Drugs, 2004, 18 :561-574
[42]   The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment [J].
Phillips, CJ .
CNS DRUGS, 2004, 18 (09) :561-574
[43]   Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis [J].
Rezaee, Mehdi ;
Ravangard, Ramin ;
Mojtabaeian, Seyyed Morteza ;
Jafari, Abdosaleh .
BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
[44]   Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis [J].
Kim, Su-Hyun ;
Park, Min Su ;
Kim, Woojun ;
Huh, So-Young ;
Shin, Hyun-June ;
Hyun, Jae-Won ;
Kim, Ho Jin .
JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (01) :20-26
[45]   COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE [J].
Gourzoulidis, G. ;
Kourlaba, G. ;
Andreadou, E. ;
Karageorgiou, K. ;
Maniadakis, N. .
VALUE IN HEALTH, 2018, 21 :S339-S339
[46]   Oral disease-modifying therapies for relapsing-remitting multiple sclerosis [J].
Thomas, Rachel Hutchins ;
Wakefield, Richard A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) :25-38
[47]   Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review [J].
Gallehzan, Nasrin Abulhasanbeigi ;
Khosravi, Majid ;
Jamebozorgi, Khosro ;
Mir, Nazanin ;
Jalilian, Habib ;
Soleimanpour, Samira ;
Hoseini, Saeed ;
Rezapour, Aziz ;
Eshraghi, Abbas .
HEALTH ECONOMICS REVIEW, 2024, 14 (01)
[48]   Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis [J].
Becker, Russell V., III ;
Dembek, Carole .
JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (05) :377-381
[49]   Disease-modifying therapies for multiple sclerosis [J].
De Angelis, Floriana ;
John, Nevin A. ;
Brownlee, Wallace J. .
BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
[50]   Multiple sclerosis and disease-modifying therapies [J].
Minen, Mia T. ;
Karceski, Steven .
NEUROLOGY, 2011, 77 (04) :E26-E26
12345